Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03526367

A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI

A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of Contrast Induced Acute Kidney Injury in Patient With Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention (TRACK-AMI)

Status
Withdrawn
Phase
Phase 4
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Shenyang Northern Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The CIAKI,as the third complication of PCI, was associated with adverse cardiac events after procedure. Moreover, because the rate of periprocedure hydration is inadequate in STEMI patients before primary PCI, the incidence of CIAKI is higher significantly in these patients. The cardiovascular pleiotropic effects of statins in addition to lipid have been widely concerned. The previous studies demonstrated usage of statin in periprocedure could decrease the risk of CIAKI. Compared with hydration, the usage of statin to prevention CIAKI show the advantages in clinical practice, for example,there is no need to consider the cardiac function.The optimal strategies for preventting CIAKI in STEMI patients undergoing primary PCI needed further studies to explore. What's more, whether a synergistic effect of hydration and statin or not is unknown.

Conditions

Interventions

TypeNameDescription
DRUGhydration plus rosuvastatin therapyIn experimental group,a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days and hydration(3ml/kg/h)last 12 hours after randomized
DRUGStandard therapyProhibition of use any statins from randomized to 12 hours after procedure; The hydration or not is determined by physicians but 1 ml/kg/h at most.

Timeline

Start date
2019-02-20
Primary completion
2019-12-31
Completion
2019-12-31
First posted
2018-05-16
Last updated
2019-09-19

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03526367. Inclusion in this directory is not an endorsement.